• MyD88 L265P is present in the extracellular vesicles (EVs) secreted by WM cancer cells and triggers signaling in the recipient cells
Abstract
The link between inflammation and cancer is particularly strong in Waldenström's macroglobulinaemia (WM), a diffuse large B-cell lymphoma, wherein the majority of patients harbor a constitutively active mutation in the innate immune signaling adaptor 
Introduction
MyD88 is a signaling adapter protein that plays a pivotal role in innate immunity. MyD88 is recruited to the TIR domains of activated Toll-like receptors (TLRs) and interleukin-1/18
receptor (IL-1R, IL-18R), leading to myddosome complex formation with IRAK4 and IRAK1/2 kinases. 1, 2 Myddosome activates pathways resulting in activation of transcription factors NF-κB, AP-1, IRFs and others, which induce the transcription of numerous proinflammatory genes. 3 Patients with germline MYD88 loss-of-function mutations only survive into adulthood on strict therapy of antibiotics. 4 Conversely, somatic MYD88 gain-of-function mutations within the TIR domain of MyD88 enable constitutive activation. [5] [6] [7] MyD88Leu265Pro (MyD88  L265P ) mutation triggers spontaneous assembly of the myddosomal complex with IRAK kinases resulting in activation of STAT3, NF-κB, secretion of IL-6, IL-10 and IFNβ. 5, 8 Activating mutations in MYD88 are frequently detected in ABC subtype of DLBCL (diffused large B cell lymphoma), chronic lymphocytic leukemia and are present in more than 90% of patients with WM (Waldenström`s macroglobulinaemia). 9, 10 MyD88 L265P supports the survival of lymphoma cells by upregulating Bcl-xL expression through NF-κB pathway 11 and activation of Bruton s tyrosine kinase (BTK). 12 Inhibition of the signaling pathway downstream of MyD88 reduces proliferation of cancer cell. [5] [6] [7] The role of extracellular vesicles (EVs; comprising microvesicles (MVs) and exosomes) has been described in cancer development and dissemination of signals to other cells. 13 The number of EVs increases in stress conditions (reviewed in 14, 15 ) and increased EV levels were detected in the peripheral blood of cancer patients. 16 EVs encapsulate different cellular components including proteins, lipids, carbohydrates and noncoding regulatory RNAs, such as miRNA.
Tumor EVs promote directional cell motility through extracellular matrix (ECM) 17 and ECM remodeling. 18, 19 They also alter physiology of both surrounding and distant nontumor cells, which in turn allows growth and dissemination of cancer cells. 20, 21 However, transmission of Bone marrow derived-cultured mast cells (BMCMCs) were prepared from bone marrow cells from C57BL/6 mice using 10 ng/ml of recombinant mIL-3 (Peprotech) for 4 weeks. BMDMs were prepared from bone marrow cells from C57BL/6 mice using 40 ng/ml M-CSF for 4 days. 
Preparation of EVs

Quantitative PCR
BMCMCs, iBMDMs or BMDMs were stimulated with EVs. RNA was isolated using Trizol (Roche) or Purelink RNA mini kit (Invitrogen), cDNA was prepared using High capacity cDNA reverse transcription kit (Applied Biosystems) and qPCRs for mouse Gapdh, Rantes or Il6 were performed using SYBR green I master kit (Roche) on LightCycler 480 (Roche).
Immuno-electron microscopy
EVs were fixed with 4% formaldehyde in 0. 
Injection of EVs into the bone marrow and analysis
For personal use only. on March 16, 2018 . by guest www.bloodjournal.org From PKH67-labelled EVs were intramedullary injected into femur of C57BL/6 mice as described in Zilber et al. 28 After 16 h bones were collected and PKH fluorescence in cells was detected using CyFlow space flow cytometer (Partec). EV MWCL , EV CONT or PBS were intramedullary injected. After 8 days mice were sacrificed, blood was collected and serum was prepared (Sarstedt; 3000 rpm/30 min). Blood profile was determined from sera using VetScan comprehensive diagnostic profile reagent rotor and analyzed on VetScan VS2 (Abaxis). For rouleaux formation blood smears were prepared from a drop of whole blood using Hemacolor rapid staining of blood smear kit (Merck). Femurs were collected for immunohistochemistry.
Bones were decalcinated using 9% formic acid and embedded in paraffin (Leica Paraplast).
The paraffin blocks were cut 7 μ m thick with a rotation microtome RM 2245 (Leica). Mast cells were labelled using antiCD40L (CD154) (Biolegend) and detected by HRP-conjugated anti-goat armenian hamster (Abcam) using TMB reagent (Sigma) under Leica DMi8 with Leica MC170 HD camera.
Statistical analysis
Representative experiments are shown. For the analysis of experimental data, a t-test was used. *P < 0.1; **P < 0.05; ***P < 0.01; **** P < 0.005; n.s. -not significant.
Results
Presence of the MyD88 in EVs and transmission of the signal to the recipient cells
For the initial characterization of the ability of the MyD88 L265P mutant to be incorporated into the vesicles, the EVs were isolated from the supernatant of unstimulated MyD88
L265P
For personal use only. on March 16, 2018 . by guest www.bloodjournal.org From transfected HEK293 cells and characterized by the dynamic light scattering (DLS) (supplemental Figure 1A) , which showed the presence of MVs and exosomes. As shown by WB, EV L265P contained MyD88, which was absent from the EV CONT , isolated from the control HEK293 cells where both types of EVs contained exosomal marker Tsg101 ( Figure 1A) . In order to show that the EVs carrying the constitutively active MyD88 L265P can be taken up by the recipient cells and that this form of the delivery of MyD88 is sufficient to trigger activation of the signaling pathway in the recipient cells, activation of the NF-κB-dependent luciferase reporter was monitored in HEK293 cells. Addition of EV L265P but not EV CONT to the reporter cells activated NF-κB ( Figure 1C ) thus supporting the hypothesis that the constitutively active signaling protein can be transmitted to the recipient cells, where it can activate the signaling pathway.
MWCL-1 is a WM cell line established from the bone marrow aspirate of a WM patient. 26 We observed that MWCL-1 cells which harbor the constitutively active MyD88 L265P mutation release high amount of EVs. EV MWCL1 were isolated from the supernatant and compared to the EV L265P . As shown by DLS and TEM MWCL-1 cell line secreted EVs (exosomes and MVs) of similar size to those from HEK293 cell line (supplemental Figure 1B-C) . WB revealed the presence of MyD88 in EV MWCL , along with the exosomal marker Tsg101 ( Figure 1D ) and was not present in the cell supernatant after ultracentrifugation (supplemental Figure 1D) . Moreover, the presence of MyD88 was confirmed inside MVs by the immuno-electron microscopy ( Figure   1E ). Importantly, IRAK4, which is a constituent of the active myddosomal complex, was also detected in the EV MWCL1 ( Figure 1F ) though it was hardly detected in EV L265P ( Figure 1B) . EV L265P were submitted to several freeze/thaw cycles to disrupt the membranes of the EVs.
Freezing substantially decreased the activity ( Figure 2C ) demonstrating that the intact EVs and their content are necessary for the transfer of the signaling activity. Several mechanisms of EVmediated transfer of molecular cargo have been described. [30] [31] [32] Dynasore, an inhibitor of dynamin-mediated endocytosis, partially inhibited NF-κB activation triggered by EV L265P
( Figure 2D ). Additionally, partial inhibition of the reporter cell activation was also observed after the addition of LY294002, a PI3K inhibitor ( Figure 2E ), which inhibits phagocytosis. was added prior to the stimulation with EVs. Decrease of the NF-κB activation ( Figure 2F ) was detected, corroborating signaling in the cytosol through pathway inhibited by ibrutinib.
EV-transferred MyD88
L265P recruits the endogenous MyD88 wt to potentiate the signaling
In the previous study we showed that MyD88 L265P can recruit the MyD88 
Macrophages and mast cells respond to the MyD88 L265P containing EVs
Efficiency of the EV internalization can strongly differ between cells. EV MWCL1 were stained by a lipophilic dye PKH67 and added to several cell types. After 6 h HEK293, THP1, macrophage cell line, bone marrow derived macrophages (iBMDMs) as well as bone marrow derived mast cells (BMCMCs) were able to uptake the EVs, but no uptake was observed by B cells and Figure 5A ) as well as in organs such as liver, spleen and lungs (supplemental Figure 5B) . Moreover, to show that signaling competent MyD88 can be 
EVs carrying myddosomal complex modulate bone marrow microenvironment
Discussion
Pattern recognition receptors (PRRs) including TLRs and TLR signaling pathways have been implicated in a number of hematological malignancies (reviewed in 36 ) and in other tumors. [37] [38] [39] Although the mechanisms by which inflammation promotes neoplastic transformation are not fully understood, cancer has strong connection to chronic inflammation. 40, 41 Persistent inflammation establishes a microenvironment, which contains macrophages, dendritic cells, natural killer cells and T and B lymphocytes in addition to the surrounding stroma. 42, 43 These diverse cells communicate with each other by means of a direct contact or soluble mediators, which support cell proliferation, survival and resistance to apoptosis thus influencing the tumor formation and growth. 43, 44 EVs are able to mediate the transfer of different kinds of molecules. Due to the small amount of the cellular content transmitted by the EVs, a potent physiological effect can only be expected from the components whose activity is amplified in target cells, such as RNAs, enzymes, transcription factors (TFs) or components that could engage endogenous molecules in the target cells thus triggering the signaling cascade. As an example, TFs NF-κB and COUP-TF I were detected in MVs released from platelets and transmitted to neutrophils, but activation of target genes in recipient cells has not been investigated. 45 Here we report the transfer and activation of target cell signaling by the constitutively active MyD88 L265P as well as IRAK4 as the components of the myddosomal 
